NYSE:BSX - Boston Scientific Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.82
  • Forecasted Upside: 25.80 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
▲ +0.74 (1.99%)

This chart shows the closing price for BSX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Boston Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BSX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BSX

Analyst Price Target is $47.82
▲ +25.80% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $47.82, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 25.80% upside from the last price of $38.01.

This chart shows the closing price for BSX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in Boston Scientific. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/29/2022Canaccord Genuity GroupLower Price TargetBuy$51.00 ➝ $43.00Low
6/29/2022Canaccord Genuity GroupLower Price TargetBuy ➝ Buy$51.00 ➝ $43.00Low
6/24/2022BTIG ResearchLower Price TargetBuy$52.00 ➝ $45.00Low
5/27/2022Needham & Company LLCUpgradeHold ➝ Buy$48.00Low
5/24/2022BTIG ResearchReiterated RatingBuy$52.00Low
5/17/2022CitigroupLower Price TargetBuy$52.00 ➝ $47.00N/A
4/13/2022Truist FinancialInitiated CoverageBuy$52.00Low
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ BuyMedium
2/3/2022Morgan StanleyLower Price TargetOverweight$53.00 ➝ $51.00Low
2/3/2022Raymond JamesLower Price TargetStrong-Buy$51.00 ➝ $49.00High
2/3/2022SVB LeerinkLower Price TargetMarket Perform$48.00 ➝ $45.00High
12/21/2021Truist FinancialBoost Price TargetBuy$52.00 ➝ $53.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$51.00Low
10/28/2021Raymond JamesLower Price TargetStrong-Buy$53.00 ➝ $51.00Medium
9/21/2021Morgan StanleyReiterated RatingBuy$53.00Medium
7/28/2021Credit Suisse GroupBoost Price TargetOutperform$50.00 ➝ $52.00Low
7/28/2021Raymond JamesBoost Price TargetStrong-Buy$50.00 ➝ $53.00Low
7/28/2021Morgan StanleyBoost Price TargetOverweight$51.00 ➝ $53.00Low
7/15/2021Needham & Company LLCSet Price TargetHold$42.74Medium
6/7/2021ArgusBoost Price TargetBuy$45.00 ➝ $50.00Low
5/26/2021Needham & Company LLCDowngradeBuy ➝ HoldHigh
5/24/2021BarclaysInitiated CoverageOverweight$51.00Low
4/29/2021Truist FinancialBoost Price Target$42.00 ➝ $50.00Low
4/29/2021Morgan StanleyBoost Price TargetOverweight$43.00 ➝ $51.00Low
4/29/2021Wells Fargo & CompanyBoost Price TargetIn-Line ➝ Overweight$42.00 ➝ $50.00Low
4/29/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$39.00 ➝ $45.00Low
4/15/2021Atlantic SecuritiesInitiated CoverageOverweight$52.00High
2/12/2021Needham & Company LLCBoost Price TargetBuy$43.00 ➝ $46.00Low
2/4/2021Raymond JamesBoost Price TargetStrong-Buy$39.00 ➝ $43.00Low
2/3/2021Piper SandlerBoost Price TargetIn-Line ➝ Overweight$46.00 ➝ $48.00High
2/1/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
12/15/2020Morgan StanleyBoost Price TargetOverweight$40.00 ➝ $43.00Low
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
12/8/2020BTIG ResearchReiterated RatingBuyLow
11/18/2020Truist FinancialLower Price Target$47.00 ➝ $44.00Medium
11/18/2020Smith Barney CitigroupLower Price Target$46.00 ➝ $43.00High
11/18/2020Wells Fargo & CompanyLower Price TargetOverweight$44.00 ➝ $41.00High
11/18/2020Morgan StanleyLower Price TargetOverweight$41.00 ➝ $40.00High
11/17/2020Needham & Company LLCLower Price TargetBuy$50.00 ➝ $43.00High
10/29/2020Morgan StanleyLower Price TargetOverweight$48.00 ➝ $41.00High
9/17/2020Truist FinancialInitiated CoverageBuy$47.00 ➝ $47.00High
9/11/2020Wolfe ResearchInitiated CoverageMarket Perform$46.00Medium
7/30/2020Stifel NicolausBoost Price TargetBuy$45.00 ➝ $47.00Low
7/30/2020Jefferies Financial GroupBoost Price TargetBuy$43.00 ➝ $46.00Low
7/30/2020CitigroupBoost Price TargetBuy$44.00 ➝ $46.00Medium
7/30/2020SVB LeerinkBoost Price TargetMarket Perform$40.00 ➝ $43.00Medium
7/30/2020Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $48.00Medium
7/29/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
7/29/2020OppenheimerBoost Price TargetMarket Perform$41.00 ➝ $43.00Medium
6/24/2020Stifel NicolausReiterated RatingBuy$45.00Low
5/13/2020ArgusBoost Price TargetBuy$40.00 ➝ $42.00Low
4/30/2020CSFBBoost Price TargetOutperform$42.00 ➝ $43.00High
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$40.00 ➝ $41.00Low
4/30/2020Credit Suisse GroupBoost Price TargetOutperform$42.00 ➝ $43.00Low
4/30/2020CitigroupBoost Price TargetBuy$40.00 ➝ $42.00Medium
4/30/2020UBS GroupLower Price TargetBuy$50.00 ➝ $45.00Medium
4/30/2020Stifel NicolausBoost Price TargetBuy$35.00 ➝ $45.00Medium
4/30/2020Raymond JamesBoost Price TargetStrong-Buy$42.00 ➝ $43.00High
4/30/2020OppenheimerReiterated RatingHold$46.00 ➝ $41.00Low
4/29/2020BTIG ResearchReiterated RatingBuy$44.00Low
4/29/2020Needham & Company LLCReiterated RatingBuy$46.00Low
4/23/2020SunTrust BanksLower Price TargetBuy$28.00 ➝ $25.00Low
4/22/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$40.00Low
4/9/2020Raymond JamesLower Price TargetStrong-Buy$49.00 ➝ $42.00High
4/2/2020Piper SandlerReiterated RatingBuyLow
4/2/2020Needham & Company LLCLower Price TargetBuy$53.00 ➝ $43.00Medium
4/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-Buy$46.00 ➝ $38.00High
3/27/2020CitigroupLower Price TargetBuy$48.00 ➝ $40.00Low
3/24/2020Stifel NicolausLower Price TargetBuy$47.00 ➝ $30.00High
3/23/2020StephensLower Price TargetOverweight$48.00 ➝ $35.00High
3/9/2020CfraUpgradeBuy ➝ Strong-Buy$50.00 ➝ $47.00Low
3/6/2020Credit Suisse GroupLower Price TargetOutperform$51.00 ➝ $46.00High
3/4/2020CitigroupInitiated CoverageBuy$48.00High
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$46.00Low
2/6/2020BTIG ResearchInitiated CoverageBuy$46.00Low
1/15/2020CowenReiterated RatingBuy$52.00Medium
1/14/2020Piper SandlerReiterated RatingBuyLow
12/30/2019CowenBoost Price TargetOutperform$47.00 ➝ $52.00Low
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$50.00 ➝ $55.00Low
12/19/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$53.00Low
12/17/2019Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $51.00Medium
12/16/2019Wells Fargo & CompanyBoost Price TargetOverweight$48.00 ➝ $52.00Low
10/25/2019GuggenheimSet Price TargetBuy$53.00N/A
10/23/2019Needham & Company LLCReiterated RatingBuy$53.00Medium
10/14/2019Raymond JamesLower Price TargetStrong-Buy$50.00 ➝ $48.00Low
9/30/2019StephensSet Price TargetBuy$48.00Low
9/6/2019Stifel NicolausSet Price TargetBuy$47.00High
9/5/2019JPMorgan Chase & Co.Initiated CoverageOverweightMedium
9/3/2019BarclaysReiterated RatingOverweight$48.00High
8/30/2019Stifel NicolausSet Price TargetBuy$46.00Low
8/29/2019Morgan StanleySet Price TargetBuy$50.00Low
7/31/2019SVB LeerinkSet Price TargetBuy$50.00Low
7/25/2019Raymond JamesBoost Price TargetStrong-Buy$48.00 ➝ $50.00Medium
7/24/2019Needham & Company LLCSet Price TargetBuy$46.00Low
7/24/2019BTIG ResearchSet Price TargetBuy$46.00Low
7/24/2019Piper Jaffray CompaniesSet Price TargetBuy$50.00Low
6/27/2019Stifel NicolausBoost Price TargetBuy ➝ In-Line$44.00 ➝ $46.00Medium
6/27/2019Jefferies Financial GroupBoost Price TargetBuy ➝ Positive$44.00 ➝ $48.00Medium
6/27/2019Piper Jaffray CompaniesBoost Price TargetOverweight$42.00 ➝ $50.00Medium
6/18/2019Wells Fargo & CompanyBoost Price TargetOutperform$42.00 ➝ $45.00Medium
5/13/2019Evercore ISIUpgradeIn-Line ➝ Outperform$36.20Low
5/13/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
4/25/2019BTIG ResearchReiterated RatingBuyHigh
2/13/2019ArgusBoost Price TargetBuy$43.00 ➝ $45.00Medium
2/8/2019SunTrust BanksReiterated RatingBuy$47.00Low
2/8/2019GuggenheimReiterated RatingBuy$48.00Low
2/6/2019Needham & Company LLCReiterated RatingBuy$43.00Low
1/8/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$42.00Low
11/27/2018UBS GroupInitiated CoverageBuy ➝ Buy$45.00High
11/21/2018OppenheimerReiterated RatingHoldLow
11/21/2018BTIG ResearchReiterated RatingBuyLow
11/20/2018SunTrust BanksBoost Price TargetBuy$44.00Low
11/19/2018StephensReiterated RatingIn-Line ➝ Market Perform$40.00Medium
11/16/2018GuggenheimBoost Price TargetBuy$45.00Low
10/26/2018ArgusBoost Price TargetBuy ➝ Buy$41.00 ➝ $43.00Low
10/25/2018BTIG ResearchReiterated RatingBuy$45.00Medium
10/24/2018OppenheimerSet Price TargetHold$38.00Medium
10/22/2018CowenSet Price TargetBuy$39.00 ➝ $42.00Low
10/16/2018BTIG ResearchReiterated RatingBuy$45.00High
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$43.00High
10/15/2018Royal Bank of CanadaBoost Price TargetTop Pick$42.00High
10/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$38.00 ➝ $48.00Low
9/25/2018OppenheimerReiterated RatingHoldMedium
9/17/2018Wells Fargo & CompanyBoost Price TargetOutperform$38.00 ➝ $42.00Low
9/7/2018Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$39.00 ➝ $43.00Low
9/5/2018ArgusBoost Price TargetBuy$41.00Low
9/4/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$40.00 ➝ $41.00Low
9/4/2018Jefferies Financial GroupUpgradeHold ➝ Buy$34.00 ➝ $42.00Low
7/27/2018GuggenheimReiterated RatingBuy$43.00Low
7/26/2018Stifel NicolausReiterated RatingBuy$37.00Low
7/26/2018Jefferies Financial GroupReiterated RatingHold$34.00Low
7/26/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$33.00 ➝ $38.00Low
7/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$38.00Low
7/23/2018Royal Bank of CanadaBoost Price TargetTop Pick$36.00Low
7/23/2018SunTrust BanksBoost Price TargetBuy$39.00Low
7/10/2018BMO Capital MarketsBoost Price TargetOutperform$36.00High
7/6/2018Needham & Company LLCReiterated RatingStrong-BuyMedium
6/27/2018Sanford C. BernsteinInitiated CoverageOutperform$38.00Low
6/7/2018ArgusBoost Price TargetBuy ➝ Buy$32.00 ➝ $36.00Medium
5/1/2018CitigroupBoost Price TargetBuy ➝ Buy$32.00 ➝ $34.00Low
4/26/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$32.00 ➝ $34.00Low
4/26/2018Jefferies Financial GroupReiterated RatingHold$31.00Low
4/26/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$35.00 ➝ $36.00Low
4/26/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $33.00Low
4/26/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $32.00Low
4/5/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$30.00 ➝ $34.00Low
3/27/2018Needham & Company LLCReiterated RatingBuy$35.00High
3/19/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $33.00Low
3/5/2018Royal Bank of CanadaReiterated RatingTop Pick$32.00Medium
2/23/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$31.00Medium
2/2/2018Jefferies Financial GroupReiterated RatingHold ➝ NeutralLow
1/16/2018Needham & Company LLCReiterated RatingBuy$32.00Low
1/10/2018BarclaysReiterated RatingBuy$32.00Low
1/5/2018Royal Bank of CanadaUpgradeOutperform ➝ Top PickMedium
1/3/2018Evercore ISIInitiated CoverageIn ➝ In-Line$27.00Medium
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00Low
12/8/2017Needham & Company LLCUpgradeBuy ➝ Strong-Buy$25.04 ➝ $32.00Low
12/4/2017SunTrust BanksSet Price TargetBuy$33.00Low
11/30/2017CowenSet Price TargetBuy$31.00Low
11/30/2017BTIG ResearchUpgradeNeutral ➝ Buy$31.00Medium
11/29/2017BMO Capital MarketsReiterated RatingBuy$31.00Medium
11/29/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
11/29/2017OppenheimerReiterated RatingHoldHigh
11/7/2017Royal Bank of CanadaReiterated RatingBuy$31.00N/A
10/31/2017SunTrust BanksSet Price TargetBuy$34.00N/A
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$30.00 ➝ $32.00N/A
10/13/2017BMO Capital MarketsReiterated RatingBuy$30.00N/A
10/3/2017Needham & Company LLCReiterated RatingBuy$32.00Low
10/2/2017SunTrust BanksReiterated RatingBuy$34.00Medium
9/25/2017Stifel NicolausReiterated RatingBuy$32.00Low
9/7/2017Jefferies Financial GroupReiterated RatingHoldLow
9/1/2017Royal Bank of CanadaReiterated RatingBuy$31.00N/A
8/9/2017OppenheimerReiterated RatingHoldMedium
8/1/2017UBS GroupReiterated RatingBuy$30.00 ➝ $31.00Low
7/30/2017Stifel NicolausReiterated RatingBuy$32.00Medium
7/28/2017OppenheimerSet Price TargetHold$29.00Low
7/28/2017CowenReiterated RatingBuy$31.00 ➝ $32.00Low
7/17/2017CowenReiterated RatingOutperform$31.00Low
7/12/2017Royal Bank of CanadaReiterated RatingBuy$31.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 32 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $38.01
Low: $37.09
High: $38.11

50 Day Range

MA: $39.22
Low: $35.24
High: $43.06

52 Week Range

Now: $38.01
Low: $34.98
High: $47.49


224,386 shs

Average Volume

8,789,882 shs

Market Capitalization

$54.34 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Boston Scientific?

The following Wall Street analysts have issued reports on Boston Scientific in the last twelve months: Bank of America Co., BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Credit Suisse Group AG, Morgan Stanley, Needham & Company LLC, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TheStreet, and Truist Financial Co..
View the latest analyst ratings for BSX.

What is the current price target for Boston Scientific?

0 Wall Street analysts have set twelve-month price targets for Boston Scientific in the last year. Their average twelve-month price target is $47.82, suggesting a possible upside of 25.8%.
View the latest price targets for BSX.

What is the current consensus analyst rating for Boston Scientific?

Boston Scientific currently has 1 hold rating, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BSX will outperform the market and that investors should add to their positions of Boston Scientific.
View the latest ratings for BSX.

How do I contact Boston Scientific's investor relations team?

Boston Scientific's physical mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is (508) 683-4000 and its investor relations email address is bsxinvesto[email protected] The official website for Boston Scientific is www.bostonscientific.com. Learn More about contacing Boston Scientific investor relations.